2 Years of Endocrine Therapy, 2 Decades of Protection From Metastatic Breast Cancer
(MedPage Today) -- Two years of adjuvant endocrine therapy for premenopausal breast cancer protected against metastatic recurrence for 20 years, a new analysis of a randomized trial showed.
Premenopausal women who received goserelin, tamoxifen... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 1, 2022 Category: Hematology Source Type: news
Episode 7: Adjuvant Endocrine Therapy Episode 7: Adjuvant Endocrine Therapy
Drs Lidia Schapira and Norah Lynn Henry discuss adjuvant endocrine therapy.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 14, 2022 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
Sexual Dysfunction Post Breast Cancer Treatment Explained Sexual Dysfunction Post Breast Cancer Treatment Explained
Adjuvant endocrine therapy for early breast cancer is associated with sexual dysfunction, particularly in women who have had a mastectomy and in women with physical and endocrine disorder symptoms.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 6, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
ASCO 2022: Immediate Options for Endocrine Therapy-Refractory Patients With HER2-Low Metastatic Breast Cancer ASCO 2022: Immediate Options for Endocrine Therapy-Refractory Patients With HER2-Low Metastatic Breast Cancer
Tarah J. Ballinger, MD, discusses the implications of the DESTINY-Breast 04 trial and the immediate impact that it will have on the lives of her patients.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2022 Category: Consumer Health News Tags: None MDAngle Source Type: news
Select Patients With Breast Cancer May Skip RT After Lumpectomy Select Patients With Breast Cancer May Skip RT After Lumpectomy
Older patients with low-grade, luminal A-type breast cancer may only need endocrine therapy following breast-conserving surgery and could avoid radiation therapy entirely.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Endocrine Switch Plus Ribociclib Active in Post-CDK4/6 Inhibitor Progression
(MedPage Today) -- CHICAGO -- Progression-free survival (PFS) in advanced hormone receptor (HR)-positive/HER2-negative breast cancer improved significantly in patients who received ribociclib (Kisqali) and a different endocrine therapy after... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 6, 2022 Category: Hematology Source Type: news
Adjuvant Everolimus Fails to Stop Recurrence in Early High-Risk Breast Cancer
(MedPage Today) -- Adding mTOR inhibitor everolimus (Afinitor) to adjuvant endocrine therapy failed to improve disease-free survival (DFS) in high-risk hormone receptor-positive/HER2-negative (HR+/HER2-), a large randomized trial showed.
Three... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 2, 2022 Category: Hematology Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data on glofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onc...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onco...
Source: Roche Investor Update - May 24, 2022 Category: Pharmaceuticals Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news
Database of wrist fractures should boost AI research
Efforts to develop artificial intelligence (AI) algorithms to help diagnos...Read more on AuntMinnie.comRelated Reading:
AI model can help diagnose pediatric buckle fractures
Bone fractures are common after breast cancer endocrine therapy
AI algorithm detects troublesome wrist fractures on x‑rays
AI comparable to rads for interpreting wrist x-rays
AI can detect, localize fractures on wrist x-rays (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 23, 2022 Category: Radiology Source Type: news
Sarcopenia Nearly Doubles Risk Women Will Quit Endocrine Therapy Sarcopenia Nearly Doubles Risk Women Will Quit Endocrine Therapy
But the good news is oncologists can address the condition before starting therapy. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 17, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Breast Cancer Test Recommended for Extended Endocrine Therapy Breast Cancer Test Recommended for Extended Endocrine Therapy
The Breast Cancer Index is the only genomic test that should be used to guide extended endocrine therapy decisions for women with early-stage, hormone receptor –positive breast cancer, says ASCO.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - May 10, 2022 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Gene Score, Endocrine Response Can Guide Early Breast Cancer Therapy
(MedPage Today) -- Use of the 21-gene recurrence score (RS) combined with response to 3-week preoperative endocrine therapy can be used to guide systemic therapy in early breast cancer patients with limited nodal involvement, and can help avoid... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 17, 2022 Category: Hematology Source Type: news
